Shahneen Sandhu

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Christopher J Sweeney, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath, Anthony M Joshua, Nicola J Lawrence, Gavin M Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A North, Francis Parnis, Wendy Parulekar, David W Pook, et al.

Journal article  |  2021  |  EUROPEAN UROLOGY

Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than me..

CX-5461 sensitises DNA damage repair proficient castrate-resistant prostate cancer to PARP inhibition.

Mitchell G Lawrence, Laura H Porter, Nicholas Choo, David Pook, Jeremy P Grummet, Carmel J Pezaro, Shahneen Sandhu, Susanne Ramm, Jennii Luu, Andrew Bakshi, David L Goode, Elaine Sanij, Richard B Pearson, Ross D Hannan, Kaylene J Simpson, Renea A Taylor, Gail P Risbridger, Luc Furic

Journal article  |  2021  |  Mol Cancer Ther

Monotherapy with poly (ADP-ribose) polymerase (PARP) inhibitors is effective for the subset of castrate-resistant prostate cancer ..

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Gail P Risbridger, Ashlee K Clark, Laura H Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L Lister, David Pook, Carmel J Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B Madsen, Hong Wang, Michelle G Richards, Birunthi Niranjan, Samantha O'Dea, Linda Teng, William Wheelahan, et al.

Journal article  |  2021  |  NATURE COMMUNICATIONS

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-d..

Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.

Shahneen Sandhu, Christina Guo, Michael S Hofman

Journal article  |  2021  |  J Nucl Med

Despite significant advances in prostate cancer therapeutic development over the last two decades, metastatic prostate cancer rema..

Targeted radioactive therapy for prostate cancer reply

Michael S Hofman, Shahneen Sandhu, Roslyn J Francis, Ian D Davis, Louise Emmett

Journal article  |  2021  |  LANCET

Prostate cancer.

Shahneen Sandhu, Caroline M Moore, Edmund Chiong, Himisha Beltran, Robert G Bristow, Scott G Williams

Journal article  |  2021  |  Lancet

The management of prostate cancer continues to evolve rapidly, with substantial advances being made in understanding the genomic l..

Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series

Amir Iravani, Catherine Mitchell, Tim Akhurst, Shahneen Sandhu, Michael S Hofman, Rodney J Hicks

Journal article  |  2021  |  CLINICAL GENITOURINARY CANCER

• Molecular imaging targeting the prostate-specific membrane antigen, somatostatin receptor subtype 2, and glycolytic pathway may ..

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma reply

Ines Pires da Silva, Tasnia Ahmed, Irene LM Reijers, Allison Betof Warner, James Randall Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Lisa Zimmer, Claudia Trojaniello, Oliver Klein, Camille L Gerard, Olivier Michielin, Andrew Haydon, Paolo A Ascierto, Matteo S Carlino, Celeste Lebbe, Paul Lorigan, Douglas B Johnson, Shahneen Sandhu, et al.

Journal article  |  2021  |  LANCET ONCOLOGY

Original Research Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy

Helen Dearden, Lewis Au, Daniel Y Wang, Lisa Zimmer, Zeynep Eroglu, Jessica L Smith, Marcello Cuvietto, Chloe Khoo, Victoria Atkinson, Serigne Lo, Georgina V. Long, Shahneen Sandhu, Paolo A Ascierto, Matteo S Carlino, Douglas B Johnson, James Larkin, Alexander M Menzies

Journal article  |  2021  |  EUROPEAN JOURNAL OF CANCER

BACKGROUND: Combination ipilimumab and nivolumab is approved for several malignancies. Toxicity most often occurs 6-10 weeks into ..

Nomograms to predict outcomes after Lu-177-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Andrei Gafita, Jeremie Calais, Tristan R Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R Armstrong, Andrew Robertson, Pan Thin, Calogero D'Alessandria, Matthew B Rettig, Ebrahim S Delpassand, Uwe Haberkorn, David Elashoff, et al.

Journal article  |  2021  |  LANCET ONCOLOGY

BACKGROUND: Lutetium-177 (177Lu) prostate-specific membrane antigen (177Lu-PSMA) is a novel targeted treatment for patients with m..